SCHEMBL2174190

SCHEMBL2174190

O=c1ccccn1Cc1ccc(Cl)cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
SIGMAR1 Q99720 1/20 0.53
DBH P09172 1/20 0.50
MEN1 O00255 2/20 0.47
PKM P14618 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
KDM4E B2RXH2 2/20 0.46
CYP2A13 Q16696 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
GLA P06280 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179428 0.83 DBH (0.53) NPSR1DBHMEN1PKMKMT2A
SCHEMBL16881160 0.83 POLB (0.53) POLBNPSR1SIGMAR1MEN1PKM
SCHEMBL28003319 0.83 POLB (0.69) POLBNPSR1SIGMAR1LMNASMN1; SMN2
SCHEMBL16881528 0.82 POLB (0.51) POLBNPSR1MEN1PKMKMT2A
SCHEMBL28380112 0.81 POLB (0.50) POLBNPSR1MEN1KMT2ALMNA
SCHEMBL16881360 0.79 POLB (0.55) POLBNPSR1LMNAHTTSMN1; SMN2
SCHEMBL2175264 0.78 KMT2A (0.51) NPSR1DBHMEN1PKMKMT2A
SCHEMBL4591947 0.78 POLB (0.61) POLBNPSR1SIGMAR1MEN1KMT2A
SCHEMBL16891467 0.77 POLB (0.46) POLBNPSR1MEN1KMT2ALMNA
SCHEMBL9752644 0.77 POLB (0.58) POLBNPSR1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973060-B2 Fab I inhibitor and process for preparing same CRYSTALGENOMICS, INC. (KR) 2011-07-05 US disclosed
EP-1948601-A1 FAB I INHIBITOR AND PROCESS FOR PREPARING SAME Crystalgenomics, Inc. (KR) 2008-07-30 EP disclosed
US-20070135465-A1 Fab I Inhibitor and Process for Preparing Same CRYSTALGENOMICS, INC. (KR) 2007-06-14 US disclosed
WO-2007043835-A1 FAB I INHIBITOR AND PROCESS FOR PREPARING SAME CRYSTALGENOMICS, INC. (KR) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135465-A1 Fab I Inhibitor and Process for Preparing Same TFPI, TFPI2, FCGRT POLB 1080/4885NPSR1 4162/4885SIGMAR1 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.